Lv1
60 积分 2021-09-26 加入
NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
14小时前
待确认
Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
14小时前
已完结
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
3个月前
已完结
Polypharmacology – Foe or Friend?
4个月前
已完结
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2
8个月前
已完结
EZH2 promotes proliferation and invasiveness of prostate cancer cells
8个月前
已完结
EZH1/2 as targets for cancer therapy
8个月前
已完结
皖公网安备34019202002308
